Search Videos and More
News
Live Cell Imaging IDs Bad Actors in Cancer and Finds Possible Ways to Defeat Them
Most forms of chemotherapy are designed to kill cancer cells. But some cancer cells survive. Those that do can cause the cancer to relapse.
News
Origins of Glioma Brain Cancer Found to be in the Epigenome
While cancers often originate from mutations and other alterations of cells' DNA, researchers in the Bernstein Laboratory at Dana-Farber and the Broad Institute of MIT and Harvard have found that gliomas – incurable brain tumors – can arise due to changes in the epigenome, the collection of compounds that are deposited on DNA and alter gene activity without changing the sequence of DNA itself.
News
Obesity and High Weight Linked to Adverse Outcomes In Leukemia Treatment
As the United States faces a growing obesity epidemic, scientists are taking a closer look at how body weight can affect health outcomes.
News
Study Suggests Lymphoma Patients with Depression or Anxiety Experience Shorter Survival Times
Patients with depression and/or anxiety prior to a diagnosis of diffuse large B-cell lymphoma (DLBCL) had shorter survival times than patients without a mental health diagnosis, according to a retrospective study led by Dana-Farber Cancer Institute researchers and published in The Lancet Hematology.
News
Study Uncovers Role of Ultraviolet Radiation in Development of Rare Leukemia in the Skin
A change of scenery can restore one's outlook, but for some precancerous cells, a journey from the caves of the bone marrow to the sunny climes of the skin can trigger genetic changes that are a harbinger of cancer, according to a new study by researchers at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and the Broad Institute of MIT and Harvard.
News
New Clinical Tool for Clonal Hematopoiesis Identifies Patients at High Risk for Blood Cancer
A new clinical tool developed by a team of researchers led by the Dana-Farber Cancer Institute pinpoints which Clonal hematopoiesis patients are at highest risk for cancer progression.
News
High Concentrations of Immune Cells Within Tumors Associated with Longer Patient Survival
ImmunoPROFILE: A prospective implementation of clinically validated, quantitative immune cell profiling test identifies tumor-infiltrating CD8+ and PD-1+ cell densities as prognostic biomarkers across a 2,023 patient pan-cancer cohort treated with different therapies
News
Clinical Trial Shows That Adding Bevacizumab to Targeted Drug and Chemotherapy Produces Striking Activity Against HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
Long-term results and ctDNA correlatives for CAPOX BETR: A multi-center phase II trial of capecitabine, oxaliplatin, bevacizumab and trastuzumab for previously untreated HER2 positive metastatic gastroesophageal adenocarcinoma
News
Dana-Farber Researchers Chart a Course for Understanding, Preventing, and Treating Young-Onset Colorectal Cancer
Colorectal cancer among young people is increasing globally and rapidly. Experts expect it to become the leading cause of cancer death in individuals aged 20-49 in the U.S. by the year 2030.
News
Finding Pancreatic Cancer Earlier - How Dana-Farber is Transforming the Narrative in the Early Detection and Treatment of a Stubborn Cancer
Pancreatic cancer is notoriously difficult to treat. It's commonly discovered at an advanced stage with distant metastases. But innovations in genetic testing and early detection at Dana-Farber are transforming this narrative — giving patients renewed hope for successful long-term treatment and even cures.
News
Study Unravels a Cause of Resistance to Novel Drug in Patients with Acute Leukemia
A new targeted drug has not only sparked remissions in patients with a common form of leukemia but also induced the cancer cells to reveal one of their schemes for resisting the drug, investigators at Dana-Farber Cancer Institute and other research centers report in a new pair of studies in the journal Nature.
News
Study Suggests Possible Way to ‘Smac’ Cancer
In a new study, researchers at Dana-Farber Cancer Institute used cryo-electron microscopy to reveal for the first time how one IAP, a protein called BIRC6, operates at a molecular level to inhibit programmed cell death.